Could a single HPV shot slash cervical cancer in africa?

NCT ID NCT02834637

Ongoing ⭐️ VACCINE ⭐️ Sponsor: London School of Hygiene and Tropical Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study in Tanzania tests whether one dose of the HPV vaccine works as well as the standard two or three doses in girls aged 9-14. Cervical cancer is a major killer in East Africa, and reducing the number of shots could cut costs and make vaccination more accessible. The trial will compare immune responses from different dose schedules over several years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HPV vaccine (bivalent or nonavalent)
What this could lead to: If successful, this could show that a single dose of HPV vaccine is enough to protect against cervical cancer, making vaccination cheaper and easier to deliver in low-resource areas.
What could go wrong: This is a Phase 3 trial, but results are based on immune responses, not actual cancer prevention. Infections like malaria may affect vaccine effectiveness, and long-term protection is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection Uterine Cervical Neoplasms cervical cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN PAPILLOMA VIRUS

Contacts and locations

Locations

Mwanza Intervention Trials Unit (MITU)

Mwanza, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.